Prostan/Prostan 5

Quick links to important sections

Prostan/Prostan 5

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prostan/Prostan 5

Property Description
Active ingredient Mefenamic Acid
Form Oral Capsule or Tablet
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Pain, Inflammation, and Fever Reduction
Origin Synthetic Compound

Prostan and Prostan 5 are commercial names for a medication whose single active ingredient is the chemical compound Mefenamic Acid. This medicine is consistently classified as a synthetic, single-ingredient product designed for oral administration, typically available as solid pharmaceutical forms like capsules or tablets.


What Type of Medicine is Prostan/Prostan 5?

Prostan/Prostan 5 belongs to the drug class known as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), a category of medication broadly used for pain management, inflammation reduction, and fever control. Mefenamic Acid is a member of the fenamate group of NSAIDs, which are structurally distinct as anthranilic acid derivatives. This specific structure is recognized for its analgesic properties, providing an option for various types of acute discomfort.

Its classification as an NSAID reflects its primary physiological action: the inhibition of the Cyclooxygenase (COX) enzyme system. This mechanism prevents the synthesis of prostaglandins, which are the localized chemical messengers that initiate and sustain inflammatory responses and pain signaling in the body. The medication provides analgesic and anti-inflammatory action across various pain types. The product is manufactured as a synthetic compound intended for systemic effect via oral ingestion, differentiating it from topically applied NSAID preparations.


Composition and General Purpose

The composition of Prostan/Prostan 5 consists solely of the active ingredient Mefenamic Acid, along with inactive pharmaceutical excipients that form the oral tablet or capsule matrix. The general purpose of this medication is directly linked to its chemical class, providing a combined therapeutic effect that includes analgesic (pain relief), anti-inflammatory (reduction of swelling), and antipyretic (fever reduction) properties.

The core benefit of the medication is its ability to modulate the body's inflammatory response by interrupting the chemical cascade at the prostaglandin level. This action provides relief from multiple related symptoms—pain, swelling, and fever—making it valuable for addressing various acute discomforts where these factors are present.

What side effects are possible with Prostan/Prostan 5?

Possible Side Effects and Safety Information

The safety profile for Prostan/Prostan 5 is based on official government regulatory documents, which strictly outline the known risks and documented adverse reactions.

Serious and Significant Risks

The medication carries official warnings regarding two major, potentially fatal risks:

  • Serious Cardiovascular Thrombotic Events: This includes an increased risk of heart attack (myocardial infarction) and stroke, which can be fatal. This risk may increase with the duration of use.
  • Serious Gastrointestinal (GI) Adverse Events: Events such as bleeding, ulceration, and perforation of the stomach or intestines have been reported, and these can also be fatal. Serious GI events can occur without warning symptoms at any time during use.

Common Adverse Reactions

Adverse reactions reported frequently in clinical trials include:

  • Gastrointestinal symptoms, such as diarrhea, constipation, and abdominal pain.
  • Headache.
  • Indigestion or heartburn.

Contraindications and Safety Limitations

Prostan/Prostan 5 is contraindicated (must not be used) in certain patient groups due to heightened risk. These include individuals with:

  • Active gastrointestinal bleeding or ulceration.
  • Severe, uncontrolled heart failure or established thromboembolic disease.
  • The setting of coronary artery bypass graft (CABG) surgery.
  • Known hypersensitivity to the drug or other medications in the same class.
  • Use in late pregnancy.

Regulatory documentation indicates that to minimize the potential risk for a serious cardiovascular adverse event, the lowest effective dose should be used for the shortest possible duration. Rare but severe adverse reactions have also been documented, including severe skin reactions and anaphylactic-like reactions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Mefenamic Acid overdose focuses on severe, acute manifestations across major physiological systems. Overdose situations have been formally associated with potentially life-threatening outcomes and require immediate attention, as explicitly stated in prescribing information.

Documented Manifestations Severe Outcomes and Management
CNS: Seizures, extreme tiredness, confusion, vertigo, or hallucinations. Severe Risk: Coma, acute renal failure, and fatalities have been documented in regulatory records.
GI: Nausea, vomiting, severe stomach pain, or signs of bleeding (e.g., bloody vomit, black or tarry stools). Supportive Care: Treatment is entirely symptomatic and supportive. No specific antidote is known or officially listed.

When to Seek Urgent Medical Help

Immediate emergency medical care is required if the person has collapsed, experienced a seizure, exhibits trouble breathing, or cannot be awakened. This critical guidance is explicitly stated in the regulatory documentation for overdose scenarios. Further, specific decontamination procedures, such as administering activated charcoal or gastric lavage, may be considered by medical professionals if the exposure is significant (estimated at 5 to 10 times the usual dose) or if the patient is seen within four hours of ingestion. Continuous monitoring of vital functions is essential during all phases of management.

Therapeutic Uses of Prostan/Prostan 5

What Prostan/Prostan 5 Treats: Main Uses and Benefits

Prostan/Prostan 5 (Mefenamic Acid) is commonly used to help with symptomatic relief across specific therapeutic domains where symptoms related to physical discomfort, inflammatory, or irritative states are key features. Its use is centered on offering supportive assistance when symptoms create noticeable interference with daily stability.

Mefenamic Acid is generally used for managing symptoms related to mild to moderate acute pain and primary dysmenorrhea. The medication may assist with addressing symptom clusters that appear suddenly or fluctuate, often used during phases when symptoms become more noticeable, such as dental pain, muscular aches, and discomfort following minor injuries.

It is also used to ease the challenging manifestations of painful menstrual periods and is applied in addressing symptoms of heavy bleeding (Menorrhagia). The medicine may be part of symptomatic management for conditions involving heightened systemic burden, such as easing the discomfort and stiffness of Osteoarthritis and Rheumatoid Arthritis, and playing a role in managing fever (pyrexia).

“The intent is to offer supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.”


Quick Fact: Relief for Episodic Discomfort

Prostan/Prostan 5 is used in situations involving recurrent or episodic manifestations. It is considered relevant for easing symptoms in painful, time-limited conditions like menstrual cramping and acute flares of inflammation, which may contribute to easing the overall symptom load.

Eligibility and Restrictions for Use

Who Can and Cannot Use Prostan/Prostan 5 (Mefenamic Acid)?

Regulatory authorities define strict population eligibility for Mefenamic Acid based on established risk profiles, focusing on pre-existing medical conditions and physiological state. The medicine is typically approved for adults and adolescents over 14 years old for specific pain conditions.


Absolute Contraindications

Use is strictly prohibited (contraindicated) for individuals with:

  • Hypersensitivity or allergy to Mefenamic Acid, aspirin, or any other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
  • Severe organ impairment, including severe renal, severe hepatic, or severe heart failure.
  • Active or a history of recurrent gastrointestinal ulceration, bleeding, or chronic inflammation (e.g., Inflammatory Bowel Disease).
  • The last trimester of pregnancy (after 30 weeks gestation).
  • Peri-operative pain management during Coronary Artery Bypass Graft (CABG) surgery.

Population Limitations and Restrictions

  • Age: Safety and effectiveness are not established for infants under six months of age. Use in older adults requires special caution due to an increased risk of serious complications.
  • Pregnancy/Lactation: The drug is not recommended for women attempting to conceive or while breastfeeding. Avoidance is mandatory from around 20 weeks of pregnancy.
  • Organ Function: Caution and close monitoring are required for patients with mild-to-moderate hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope: Official Regulatory Information

The official interaction profile for Prostan/Prostan 5 (Mefenamic Acid) is based on patterns documented in authoritative government regulatory sources.

Property Description
Medicinal Product Categories Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Oral Anticoagulants, Antiplatelet Agents, SSRIs, Corticosteroids, Anti-hypertensives (ACE inhibitors, AIIA, Diuretics, Beta-blockers), Lithium, and antacids containing Magnesium Hydroxide.
Mechanistic Basis (Stated in Label) Protein Binding Displacement (e.g., Warfarin); Reduced Clearance (e.g., Lithium); Additive Pharmacodynamic Risk (e.g., GI bleeding); Pharmacodynamic Antagonism (e.g., reduced anti-hypertensive efficacy).
Population-Specific Notes The risk of renal function deterioration is significantly heightened for elderly patients and those with compromised renal function when co-administered with ACE inhibitors, AIIA, and/or Diuretics.

Official Interaction Statements

  • Co-administration with other systemic non-aspirin NSAIDs is formally prohibited to mitigate the risk of serious adverse effects; use is also contraindicated in the setting of CABG surgery.
  • Co-administration with Oral Anticoagulants (e.g., Warfarin) enhances the anticoagulant response due to protein binding displacement, requiring frequent professional monitoring.
  • The medicine interferes with the anti-platelet effect of low-dose Aspirin, which may diminish its cardiovascular benefits.
  • Lithium elimination is decreased, increasing the formal regulatory risk of toxicity.
  • Anti-hypertensives and Diuretics may experience a reduction in their therapeutic efficacy.
  • Alcohol (Ethanol) is documented to increase the risk of stomach bleeding.

Connection to the Overall Interaction Profile

The regulatory interaction structure is defined by the high risk of additive pharmacodynamic effects, notably hemorrhage when combined with anti-clotting or antiplatelet agents, and pharmacokinetic modification, which formally impairs the clearance of medicines like Lithium. These patterns result in clear do-not-combine restrictions for other NSAIDs and mandatory monitoring for agents with narrow therapeutic windows.

Mechanism of Action

How Prostan/Prostan 5 Works

The mechanism of action for Prostan/Prostan 5 (Mefenamic Acid) involves the interruption of chemical signaling and the modulation of nociceptive (pain) signal pathways.

Enzyme Inhibition of the Cyclooxygenase System

This mechanism focuses on the drug’s primary action as a non-selective inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. By binding to the COX enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins, which are lipid mediators responsible for sensitizing nerve endings and promoting local inflammatory responses. This suppression of prostaglandin synthesis alters the molecular steps that shape systemic physiological outcomes.

Modulation of Nociceptive and Thermoregulatory Pathways

Beyond the peripheral actions, the mechanism also involves activity in the Central Nervous System (CNS), particularly in the hypothalamus where COX inhibition facilitates the resetting of the body's elevated temperature set point. Additionally, the drug exerts secondary non-COX effects by modulating certain ion channels and receptors (like GABA-A) involved in transmitting and processing nociceptive signals, thereby engaging mechanisms that adjust signaling patterns within neural pathways.

Dosage and Administration Information

How to Use Prostan/Prostan 5

The usage of Prostan/Prostan 5 (Mefenamic Acid) follows specific protocols regarding its route, dosage, frequency, and duration.


Administration Scope

Property Instruction
Route of Administration The medicine is for oral administration, utilizing the capsule or tablet dosage forms.
Dosing Schedule A typical regimen begins with an initial 500 mg loading dose, followed by a maintenance dose of 250 mg every six hours, as needed. The maximum daily intake is generally limited to 1000 mg to 1250 mg per day, though some guidelines permit up to 1500 mg.
Timing in Relation to Meals Dosing is typically conducted with food or milk to comply with proper administration conditions and reduce gastrointestinal factors.
Age-Group Rules The capsule and tablet forms are not recommended for use in children under 14 years of age. For older adults, the lowest effective dose for the shortest duration is advised, reflecting cautious use in this population.
Special Conditions The capsule or tablet must be swallowed whole and should not be crushed, opened, or chewed. For menstrual pain, administration is initiated at the onset of symptoms or bleeding

Use-Context Constraints

The overall use protocol emphasizes the lowest effective dose for the shortest duration. There are limitations on the length of therapy:

  • Acute Pain: Treatment duration is typically limited to seven days.
  • Primary Dysmenorrhea: Therapy is limited to two to three days per menstrual cycle.

Procedural Structure

These instructions establish a defined sequence for administration. The protocol begins with a 500 mg loading dose and continues with subsequent 250 mg maintenance doses every six hours, taken with food. The entire course of administration is time-bound according to the indication.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Clinical Trials

Research has explored whether the combination of Drug X and Compound Z was associated with changes in patient outcomes in the short term for Symptom A. Studies examined this combination across several different patient populations exhibiting Symptom A, primarily focusing on individuals with Condition C.

  • Trial Size and Duration: The majority of studies involved cohorts ranging from 50 to 300 participants, with trial durations typically spanning 4 to 12 weeks. One smaller, open-label study continued for 6 months.
  • Primary Endpoints: The primary measure of interest across the trials was change in scores on the Subjective Health Assessment Scale (SHAS) and monitoring of inflammation markers (Cytokine-1, Cytokine-2).
  • Dosing Regimens: Different amounts of Drug X and Compound Z were utilized in the initial stages of investigation.

Key Study Findings

Short-Term Impact on Symptom A

In a Phase III trial, research reported a temporary decline of inflammation markers in 80% of participants following administration of Drug X. This study evaluated whether a change occurred in the key inflammation markers related to Condition C.

Research investigated whether the combination was associated with changes in sleep quality and the need for other pain management drugs. The findings regarding sleep quality were mixed across studies, with some reporting minor changes and others reporting no statistically significant difference compared to placebo.

In one study, research explored the effects of the formulation compared with other treatments for Condition C. Studies did not address patient-specific administration timing.

Safety and Tolerability Profile

In the reviewed studies, long-term safety data were reported and no serious adverse events were noted in the majority of patients. Commonly reported findings were mild fatigue and transient gastrointestinal discomfort, which were generally observed to lessen during the initial study period.

Research did not address procedures for ending treatment. Continued research is focused on long-term tolerability and a greater understanding of patient experience.

Key Studies & References Long-term Safety and Tolerability Profile of Drug X and Compound Z in Patients with Condition C: An Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Prostan/Prostan 5 (FAQ)


Q: Can Prostan 5 be used by women?

A: Yes, Prostan 5 is approved for use in women to address specific indications, such as Primary Dysmenorrhea (menstrual pain).

Official documents outline certain restrictions regarding use during pregnancy. It is contraindicated for use during the final trimester of pregnancy due to documented risks to the developing fetus.

Q: Can Prostan 5 affect sleep patterns or cause insomnia?

A: Official regulatory documents list effects on sleep as possible adverse reactions.

Less common effects have been reported to include both somnolence (sleepiness or drowsiness) and trouble sleeping, such as insomnia. These are documented in the medication's safety profile.

Q: Is it necessary to avoid certain foods while taking Prostan?

A: The official regulatory information does not mandate the avoidance of specific foods, but it does specify a condition of use.

The medication should be taken with food or milk to minimize the potential for gastrointestinal side effects. Regulatory guidance suggests maintaining a normal diet unless specific medical instruction is provided.

Q: Does Prostan 5 work by affecting hormone levels?

A: Prostan 5 is not classified as a hormonal agent or hormone blocker.

Its mechanism involves inhibiting the synthesis of prostaglandins, which are powerful lipid mediators (chemical messengers) in the body. Prostaglandins are responsible for promoting pain and inflammation, and this action is separate from the body's primary hormonal systems.

Q: Has Prostan been studied in clinical trials involving children or adolescents?

A: Regulatory use is defined for adolescents 14 years of age and older for the medication's approved indications.

Official documents state that the safety and effectiveness of the medication are not established for children younger than 14 years of age, or for infants under six months of age.

Q: What do the major research studies indicate about the overall effectiveness of Prostan 5?

A: The medication is clinically approved for use in various types of pain management.

It is indicated to treat mild to moderate pain, including menstrual pain, and to reduce general inflammation and fever. The indications for use are based on clinical data reviewed and approved by regulatory authorities.

Q: Is Prostan 5 considered safe to handle, especially by pregnant family members?

A: The regulatory documents emphasize caution for pregnant individuals due to the documented risk of harm to an unborn child, especially in the last trimester.

While specific handling instructions for non-users are not universally provided, the product must be stored tightly closed and out of the sight and reach of children.

Q: What is the overall safety classification of Prostan according to major regulatory bodies?

A: Official US labeling includes a Boxed Warning.

This warning highlights the risk of serious cardiovascular thrombotic events (such as heart attack and stroke) and serious gastrointestinal adverse events (including bleeding, ulceration, and perforation). The classification reflects the safety profile, which is typically limited to short-term treatment as directed by a healthcare professional.

Q: Is Prostan/Prostan 5 sold as a generic name or primarily as a brand name?

A: Prostan and Prostan 5 are commercial brand names for the active ingredient, Mefenamic Acid.

Official information indicates that Mefenamic Acid is the active compound, which is widely available in both commercial brand forms and as a generic medicine.

Q: Why is Prostan sometimes called a "hormone blocker"?

A: This is a common misunderstanding related to how the drug works.

The medication works by inhibiting the production of prostaglandins, which are powerful lipid mediators that contribute to pain and inflammation. Prostaglandins are not hormones, which are signals released from glands like the thyroid or adrenal glands.

Q: What health parameters should be monitored by a doctor while taking Prostan 5?

A: Regulatory guidance advises medical monitoring, particularly for patients with certain pre-existing conditions.

Close attention is required for individuals with a history of heart failure, high blood pressure (hypertension), or existing mild-to-moderate kidney or liver impairment. This monitoring helps manage potential risks associated with the medication.

Q: What kind of monitoring or tests are typically suggested before starting Prostan 5?

A: Official regulatory texts do not list mandatory general screening tests for all users prior to starting the medication.

However, a healthcare professional assesses the individual's risk factors related to severe heart, kidney, or liver conditions before initiating treatment. This approach is part of established practice to mitigate risks associated with the medication's safety profile.

Q: How long does it usually take to notice the effects of Prostan/Prostan 5?

A: The medication is known to be rapidly absorbed by the body.

Pharmacological studies indicate that the peak plasma concentrations of the drug are typically reached within 1 to 4 hours after taking a dose. This timeframe indicates when the highest level of the drug is present in the bloodstream.

Q: Does taking Prostan 5 cause weight gain or changes in appetite?

A: Official regulatory documents report that these are potential effects related to the medication’s safety profile.

Unusual weight gain and swelling (edema) are reported as possible warning signs of serious cardiovascular issues (fluid retention). Changes in appetite are also documented as rare adverse effects.

Q: Is hair loss a documented side effect of Prostan?

A: Yes, hair loss is noted in the medication’s safety documentation.

Thinning of the hair or general hair loss has been reported as a less common adverse effect of this medication.

Q: Why does Prostan 5 cause dizziness for some people, based on official information?

A: Dizziness is officially listed as a common side effect of the medication.

Regulatory safety profiles document this effect, and it is part of the common adverse reactions reported in clinical trials.

Q: What is the procedure if a dose of Prostan is missed?

A: Official patient information outlines the recommended action for a missed dose.

Generally, if a dose is missed, regulatory information suggests taking it as soon as it is remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped.

Q: Are there any restrictions on operating machinery or driving while using Prostan 5?

A: Official regulatory documents advise caution regarding these activities.

Due to reported neurological side effects such as dizziness, nervousness, and somnolence (sleepiness), if these side effects occur, official information states that operating machinery or driving a vehicle should be avoided.

Q: Do official documents mention any effects on mood, depression, or mental health from Prostan 5?

A: Yes, the regulatory documents list mental health effects as potential adverse reactions.

Nervousness is listed as a common side effect. Less common or rare effects have included confusion, irritability, discouragement, and trouble concentrating.

How should Prostan/Prostan 5 be stored and disposed of?

How to Store and Dispose of Prostan/Prostan 5 (Mefenamic Acid)

The storage and disposal of Prostan/Prostan 5 oral capsules or tablets must strictly adhere to regulatory requirements to ensure product integrity and safety.


Official Storage Requirements

Condition Regulatory Mandate
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Must be protected from light and moisture.
Packaging Keep in the original container and ensure it is tightly closed.
Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Prostan/Prostan 5 must be disposed of according to local regulatory requirements. The product should not be disposed of via wastewater or regular household waste to prevent environmental contamination. Utilize official drug take-back programs or designated collection points when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prostan/Prostan 5 found in:

A-Z Index: